BACKGROUND. The genetic basis of susceptibility to prostate cancer (PRCA) remains elusive. Mutations in BRCA2 have been associated with increased prostate cancer risk and account for around 2% of young onset (<56 years) prostate cancer cases. PALB2 is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate PRCA susceptibility gene. METHODS. We sequenced PALB2 in probands from 95 PRCA families, 77 of which had two or more cases of early onset PRCA (age at diagnosis <55 years), and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA. RESULTS. Two previously unreported variants, K18R and V925L were identified, neither of which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic. No truncating mutations were identified. CONCLUSIONS. These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in hereditary prostate cancer. Prostate 68: [675][676][677][678] 2008. # 2008 Wiley-Liss, Inc.
INTRODUCTION
Prostate cancer is a leading cause of morbidity and mortality in men and it is diagnosed in almost onefifth of US men during their lifetime. Epidemiological studies suggest that up to 5% of all cases may be due to autosomal dominant genes [1] [2] [3] [4] , and twin studies suggest that approximately 42% of PRCA cases diagnosed under the age of 70 years are likely to be due to heritable factors [5] . Men with an affected father or brother are twice as likely to develop PRCA as men with no affected relatives [6] , and the relative risk of developing PRCA rises considerably as the number of cases in a family cluster increases and the average age at diagnosis in the cluster decreases [7] . A meta-analysis of PRCA risk among men with a positive family history found a 1.8-2.1-fold increased risk if a second degree relative is affected compared to a 2.9-fold increased risk if the father or a brother is affected [8] . The results from the Breast Cancer Linkage Consortium (BCLC) showed a RR of 4.65 (95% confidence interval, CI 3.48-6.22) of PRCA in male BRCA2 mutation carriers, data supported by a case-control study of 251 unselected Ashkenazi Jewish PRCA cases and 1,472 controls which estimated the odds ratio for PRCA in BRCA2 mutation carriers to be 4.78; 95% CI 1.87-12.25) [9] . Edwards et al. [10] screened the complete BRCA2 coding sequence in 263 British men under the age of 55 years and identified six truncating mutations (2.3%) compared to a BRCA2 mutation prevalence in the UK of a round 0.13%. From these data, they estimated that there was a 23-fold relative risk of developing prostate cancer by age 56 years in BRCA2 mutation carriers. Moreover, a recent Icelandic study has shown that PRCA arising in BRCA2 mutation carriers has a significantly worse prognosis compared to sporadic PRCA [11] . However, other groups have shown limited [12] or no association [13, 14] of BRCA2 mutations with familial PRCA.
PALB2/FANCN is a recently identified protein which interacts closely with BRCA2 [15] . This interaction is essential for BRCA2 anchorage to nuclear structures and for its function in double strand break repair by homologous recombination [15] . Recent studies have shown that, as with BRCA2, mutations in PALB2 are a cause of hereditary breast cancer [16] [17] [18] . To date, there are no published studies on PALB2 in other cancer types. In view of the close functional relationship between PALB2 and BRCA2 and their joint role in breast cancer predisposition, it is conceivable that PALB2 mutations may also predispose to PRCA and that PALB2 mutations account for a proportion of hereditary PRCA. We therefore screened PALB2 in a cohort of highly selected PRCA families.
METHODS

Study Subjects
Subjects were selected from the University of Michigan Prostate Cancer Genetics Project (PCGP), a large, ongoing, family-based study of hereditary PRCA. All participants gave written informed consent, and all consents and protocols were approved by the Institutional Review Board at the University of Michigan Medical School. To be eligible for the PCGP, families must have either two or more living members affected with prostate cancer or at least one living member with early onset PRCA (diagnosed at <55 years of age). For each participant a blood sample was taken for DNA extraction, the medical charts were reviewed and extended family history information was obtained. For the current study, 95 families with either multiple cases of early onset PRCA (defined as diagnosis prior to age 55 years) or a single case of early onset PRCA and multiple (defined as five or more) cases of PRCA diagnosed at any age were identified. Of those 95 families, 77 had two or more cases of early onset PRCA, and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA. The individual with the youngest age of diagnosis for whom DNA was available was selected from each family for PALB2 sequencing. Characteristics of the families and individuals tested are given in Tables I and II, respectively. PALB2 mutation analysis was performed by DNA sequencing as previously described [18] . Primers were designed to include an average of 75 base pairs either side of each exon, and at the 5 0 and 3 0 ends of PALB2 the analyzed sequence included 50 bases upstream of exon 1 (150 bases upstream of the translation start site) and 50 bases downstream of exon 13 (350 bases downstream of the stop codon).
RESULTS AND DISCUSSION
Probands from a total of 95 hereditary prostate cancer families were screened for PALB2 mutations and no truncating mutations were identified. A number of sequence variants were detected, the majority of which have been previously characterized [17] (Table III) and therefore it seems unlikely that these contribute to PRCA risk. Two previously unreported variants, however, were identified, namely K18R and V925L. Neither variant was located in a known functional domain of PALB2, and both were classified as ''tolerated'' using SIFT [19] . The K18R variant was found in the proband as well as his unaffected brother. Moreover, this family is of African American descent which most likely explains why the variant has not been seen in the control group screened by Rahman et al. [17] , 97% percent of which were of white ethnicity. The V925L variant was detected in both the proband and his affected brother. And as with K18R, no further samples were available from other family members. However as this amino acid change is relatively conservative (Grantham score ¼ 32), it seems unlikely that it is pathogenic.
The Prostate Our study was designed to determine whether or not PALB2 is a moderate to high penetrance gene in PRCA by screening families that were highly enriched for hereditary characteristics including early age at cancer diagnosis and/or multiple affected family members. Note that in this report, men who were tested for PALB2 mutations had a median age of prostate cancer diagnosis of 49 years, which is approximately 20 years earlier than the median age of diagnosis for sporadic PRCA. We specifically selected families from the PCGP resource with early-onset PRCA based on the findings of Edwards et al. [10] . These investigators screened 265 men with PRCA diagnosed at or before age 55 years for BRCA2 mutations and identified 6 men (2.3%) with protein truncating mutations. BRCA2 and PALB2, together with BRCA1-interacting protein (BRIP1 or FANCJ), comprise Group III Fanconi Anemia (FA) proteins [20] . These proteins appear to act downstream from the ID complex which is formed from Group II FA proteins FANCD2 and FANCI. Monoallelic mutations in all three Group III FA genes are associated with breast cancer susceptibility [21] [22] [23] . In our study we screened sufficient familial cases to have an 85% probability of detecting at least one deleterious mutation if the expected PALB2 carrier rate is 2%. This frequency is not unreasonable given that 1) our families were highly selected and enriched specifically for earlyonset PRCA, and 2) the BRCA2 mutation frequency from Edwards et al. [10] in sporadic young onset prostate cancer was 2.3%.
In their recent study Erkko et al. [16] screened 475 unselected and 164 familial (defined as having at least two affected members) PRCA cases, all from Finland, for the PALB2 1592delT founder mutation. The mean age at diagnosis in the study group was 69.5 years. They identified the mutation segregating in one family with four PRCA cases, average age at diagnosis 73.5 years. These data suggest that PALB2 may be implicated in hereditary PRCA in Finnish PRCA families. However, this does not seem to be the case in similar types of PRCA families in North America. Such geographical variation has been previously seen with other genetic variants such as CHEK2 1100delC which was found to be at increased frequency in PRCA cases from Poland [24] and Finland [25] but not southern Sweden [26] . While it is unlikely that PALB2 mutations play a major role hereditary PRCA, it may still be possible that deleterious PALB2 mutations predispose to PRCA in some rare families. However, no familial PRCA studies have shown evidence of linkage to the PALB2 locus on 16p12. It remains possible that common variants in PALB2 could be associated with a slightly increased risk for PRCA, but this study was not designed to identify such an effect.
A number of other candidate genes have been studied in hereditary prostate cancer, but BRCA2 is the only gene that has been shown to cause an increased risk of prostate cancer in multiple studies [7] . While the results of our study indicate that deleterious mutations in PALB2 do not significantly contribute to hereditary PRCA, it remains possible that other genes coding for proteins associated with BRCA2 are potential PRCA-predisposition genes.
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